ULURU Inc.

ULUR

US90403T3086

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 09:32:47 2023-08-15 EDT			5-day change	1st Jan Change
0.000001 ^USD	-.--%		-.--%	-.--%

2023	ULURU Inc. announced a financing transaction	CI
2020	ULURU Inc. will Change its Ticker to ULUR from ULURD	CI

ULURU Inc. Announces Resignation of Jeffrey B. Davis as Director

December 02, 2015 at 04:01 pm

ULURU Inc. announced the resignation of Jeffrey B. Davis as a Director of the Company, effective December 1, 2015. Mr. Davis has served as a Director of the Company since March 2006 and also as Chairman of the company's Audit Committee.

Latest news about ULURU Inc.

ULURU Inc. announced a financing transaction	23-06-29	CI
ULURU Inc. will Change its Ticker to ULUR from ULURD	20-04-20	CI
ULURU Inc. announced a financing transaction	19-11-12	CI
ULURU Inc. Announces Management Changes	18-12-07	CI
Uluru Inc. Announces Management Changes	17-04-03	CI
ULURU Inc. announced that it has received $6 million in funding from Velocitas Partners, LLC	17-03-30	CI
ULURU Inc. Announces Executive Changes	17-03-01	CI
ULURU Inc. announced that it expects to receive $6 million in funding from Velocitas Partners, LLC and other investors	17-02-26	CI
ULURU Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2016	16-11-14	CI
ULURU Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2016	16-08-16	CI
ULURU Inc. Reports Unaudited Consolidated Earnings Results for First Quarter Ended March 31, 2016	16-05-17	CI
ULURU Reports Financial Results forFirstQuarter 2016	16-05-17	CI
ULURU Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Year Ended December 31, 2015	16-03-31	CI
ULURU Inc. announced that it has received $1.8 million in funding from Centric Capital Ventures LLC	16-03-29	CI
ULURU Inc. Auditor Raises 'Going Concern' Doubt	16-03-29	CI
ULURU Appoints Terrance K. Wallberg to Board of Directors	16-03-29	CI
ULURU Inc. announced that it expects to receive $1.8 million in funding from Centric Capital Ventures LLC	16-03-28	CI
ULURU Inc. Announces Executive Changes	16-02-22	CI
ULURU Inc. Plans to Launch First Bundled Product Offering in Germany in the Second Quarter of 2016	16-02-22	CI
ULURU Inc. Announces Resignation of Kerry P. Gray as Director, Effective February 18, 2016	16-02-18	CI
ULURU Inc. cancelled the acquisition of 75% stake in Altrazeal Trading GmbH from International Pharma and Medical Devices GmbH and others.	15-12-23	CI
ULURU Inc. Announces Resignation of Jeffrey B. Davis as Director	15-12-02	CI
ULURU Inc. Announces Executive Changes	15-11-20	CI
ULURU Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015	15-11-17	CI
ULURU Inc. announced that it has received $1.27 million in funding	15-11-08	CI

Chart ULURU Inc.

Duration

Period

More charts

Company Profile

Altrazeal Life Sciences Inc., formerly ULURU Inc., is engaged in offering advanced topical solutions. The Company is a specialty medical technology company that is involved in developing and commercializing wound care and drug delivery systems based on its patented technologies. Its patented technology platforms include Altrazeal and OraDisc. Altrazeal is a new class of material designed to optimize the wound bed environment and accelerate healing. When applied to a moist wound, the powder interacts with the wound exudate and hydrates. OraDisc is a water-erodible pharmaceutical carrier device, the multi-layered device may be applied to mucosal surfaces, and adheres immediately, delivering actives to treat specific localized diseases/disorders. OraDisc technology can deliver drugs systemically across the mucosal surface or for the release of drugs into the oral cavity. The device causes minimum discomfort and provides erosion rates to deliver therapeutics over different time intervals.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ULURU INC.	-.--%	29
ELI LILLY AND COMPANY	+55.32%	815B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+13.56%	314B
ABBVIE INC.	+10.68%	303B
ASTRAZENECA PLC	+16.57%	242B
ROCHE HOLDING AG	+2.04%	224B
NOVARTIS AG	+13.31%	218B
AMGEN INC.	+8.48%	168B
PFIZER, INC.	-2.81%	159B

Other Pharmaceuticals

ULURU Inc.

Equities

ULUR

US90403T3086

Pharmaceuticals

ULURU Inc. Announces Resignation of Jeffrey B. Davis as Director

Latest news about ULURU Inc.

Chart ULURU Inc.

Company Profile

Sector Other Pharmaceuticals